UK markets closed

Cara Therapeutics, Inc. (CARA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
12.26+0.31 (+2.59%)
At close: 04:00PM EST
12.50 +0.24 (+1.96%)
After hours: 07:39PM EST

Cara Therapeutics, Inc.

4 Stamford Plaza
9th Floor 107 Elm Street
Stamford, CT 06902
United States
203 406 3700

Full-time employees84

Key executives

NameTitlePayExercisedYear born
Mr. Christopher A. PosnerPres, CEO & Director431.9kN/A1970
Dr. Derek T. Chalmers D.Sc., Ph.D.Co-Founder & Sr. Advisor580.93kN/A1964
Dr. Frédérique MenzaghiChief Scientific Officer and Sr. VP of R&D826.94kN/A1966
Mr. Scott M. TerrillionChief Compliance Officer, Gen. Counsel & Corp. Sec.689.63kN/A1963
Dr. Joana GoncalvesChief Medical Officer826.77kN/A1974
Mr. Ryan D. MaynardChief Financial OfficerN/AN/A1969
Dr. Iris Francesconi Ph.D.Chief Strategy Officer & Head of Investor RelationsN/AN/AN/A
Mr. Eric VandalSr. VP of CommercialN/AN/AN/A
Ms. Beth Weinberg R.Ph.Sr. VP of Regulatory Affairs & QAN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Corporate governance

Cara Therapeutics, Inc.’s ISS governance QualityScore as of 1 February 2023 is 7. The pillar scores are Audit: 2; Board: 6; Shareholder rights: 9; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.